// App-Quantinova.ai

3402 : BCAT1 as a druggable target in immuno-oncology

Researchers

Presenter

  • Adonia E. Papathanassiu

Principal Investigators

  • Francesca Lodi

  • Hagar Elkafrawy

  • Michelangelo Certo

  • Hong Vu

  • Jeong Hun Ko

  • Jacques Behmoaras

  • Claudio Mauro

  • Diether Lambrechts

Medical Centers

  • Vanda Pharmaceuticals, Washington, DC

  • VIB Cancer Centre-KULeuven, Leuven, Belgium

  • Alexandria University Hospital, Alexandria, Egypt

  • University of Birmingham, Birmingham, United Kingdom

Locations

  • United States

  • Belgium

  • Egypt

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gynaecological cancer

  • Colorectal Cancer

Biomarkers

  • Activating Transcription Factor 3

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Granzyme B

  • Interferon-gamma

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved